公开(公告)号：WO2018092754A1

公开(公告)日：2018-05-24

申请号：PCT/JP2017/040888

申请日：2017-11-14

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： NISHIMURA, Yasuharu ,  HIRAYAMA, Masatoshi ,  TSURUTA, Miki ,  YAMASHITA, Sachiko

IPC: C12N15/09 ,  A61K31/7088 ,  A61K35/26 ,  A61K39/00 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K16/30 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/0783 ,  C12N5/0784 ,  C12N5/10

CPC classification number: A61P35/00 ,  A61K31/7088 ,  A61K35/17 ,  A61K38/00 ,  A61K39/001184 ,  A61K2039/572 ,  A61K2039/80 ,  C07K14/4703 ,  C07K14/4748 ,  C07K16/2833 ,  C07K2317/76 ,  C12N5/0636 ,  C12N2510/00 ,  G01N33/68 ,  G01N2800/7028

Abstract: Isolated DEPDC1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce DEPDC1-specific CTLs in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, bladder cancer and breast cancer.

公开(公告)号：WO2017134137A1

公开(公告)日：2017-08-10

申请号：PCT/EP2017/052207

申请日：2017-02-02

Applicant: POLYGENE AG

Inventor： MEINZINGER, Anne Julia ,  TALLONE, Tiziano ,  SELBERT, Stefan ,  HORVATH, Peter ,  SHMERLING, Doron

IPC: C12N15/63 ,  C12N15/85

CPC classification number: C12N15/63 ,  C07K14/4703 ,  C07K14/4705 ,  C07K14/721 ,  C07K2319/00 ,  C07K2319/70 ,  C07K2319/80 ,  C12N15/85 ,  C12N2830/00 ,  C12N2830/15

Abstract: The present invention provides a regulatory fusion protein and gene regulation systems comprising such regulatory fusion protein. Further provided are cells and subjects comprising such gene regulations systems and methods of use.

Abstract translation: 本发明提供了包含这种调控融合蛋白的调控融合蛋白和基因调控系统。 还提供了包含此类基因调控系统和使用方法的细胞和受试者。

公开(公告)号：WO2016196350A1

公开(公告)日：2016-12-08

申请号：PCT/US2016/034794

申请日：2016-05-27

Applicant: NEW YORK UNIVERSITY ,  SCHNEIDER, Robert, J. ,  CHENETTE, Devon, M.

Inventor： SCHNEIDER, Robert, J. ,  CHENETTE, Devon, M.

IPC: A61P21/00 ,  C12N5/077 ,  C12N15/85 ,  C12Q1/68

CPC classification number: C12N5/0659 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0306 ,  A61P21/00 ,  C07K14/435 ,  C07K14/4703 ,  C12N15/86 ,  C12N2015/8536 ,  C12Q1/68 ,  C12Q1/6883

Abstract: The present invention relates to compositions (e.g., AUFl encoding compositions) for muscle cell uptake, satellite cell populations and compositions containing muscle satellite cell populations, pharmaceutical compositions, methods of producing muscle satellite cell compositions, and methods of causing muscle satellite cell mediated muscle generation.

Abstract translation: 本发明涉及用于肌肉细胞摄取的组合物（例如，AUF1编码组合物），卫星细胞群体和含有肌肉卫星细胞群体的组合物，药物组合物，产生肌肉卫星细胞组合物的方法以及引起肌肉卫星细胞介导的肌肉产生的方法 。

公开(公告)号：WO2016191814A1

公开(公告)日：2016-12-08

申请号：PCT/AU2016/050438

申请日：2016-06-01

Applicant: ADELAIDE RESEARCH & INNOVATION PTY LTD

Inventor： ZANNETTINO, Andrew ,  GRONTHOS, Stan ,  FITTER, Stephen

IPC: C12N5/07 ,  C12N5/0775 ,  C12N5/074 ,  C12N5/071 ,  A61K35/28 ,  C07K16/28 ,  C07K7/08

CPC classification number: C12N5/0663 ,  A61K35/28 ,  C07K14/4703 ,  C07K16/28 ,  C12N2501/07 ,  G01N33/5073 ,  G01N2500/10

Abstract: The present disclosure relates to methods and products for enriching and isolating stromal stem cells. Certain embodiments of the present disclosure provide a method of enriching for immature, uncommitted stromal stem cells from a population of cells comprising stromal stem cells, the method comprising enriching stromal stem cells from the population of cells using a HSC70 binding agent.

Abstract translation: 本公开涉及用于富集和分离基质干细胞的方法和产品。 本公开的某些实施方案提供了从包含基质干细胞的细胞群中富集未成熟的未提供的基质干细胞的方法，所述方法包括使用HSC70结合剂从细胞群体富集基质干细胞。

公开(公告)号：WO2016156596A1

公开(公告)日：2016-10-06

申请号：PCT/EP2016/057272

申请日：2016-04-01

Applicant: MOLECULAR PARTNERS AG

Inventor： BAKKER, Talitha ,  STUMPP, Michael T. ,  BINZ, Hans Kaspar ,  PHILLIPS, Douglas ,  DOLADO, Ignacio ,  FORRER, Patrik ,  MERZ, Frieder W. ,  SONDEREGGER, Ivo ,  STEINER, Daniel ,  GULOTTI-GEORGIEVA, Maya ,  ABRAM SALIBA, Johan

IPC: C07K14/475 ,  A61K38/00 ,  C07K16/22 ,  C07K16/28 ,  C07K14/765 ,  C07K14/47

CPC classification number: C07K14/001 ,  A61K38/00 ,  C07K14/47 ,  C07K14/4703 ,  C07K2318/20 ,  C07K2319/00 ,  C07K2319/31 ,  C07K2319/70 ,  C12N15/62

Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.

Abstract translation: 新设计的对血清白蛋白具有结合特异性的锚蛋白重复结构域，包含至少两个设计的针对血清白蛋白结合特异性的设计的锚蛋白重复结构域的重组结合蛋白，以及包含至少一个设计的具有对肝细胞生长具有结合特异性的设计的锚蛋白重复结构域的重组结合蛋白 描述了至少一个具有对血管内皮生长因子（VEGF-A）具有结合特异性的至少一个设计的锚蛋白重复结构域和至少两个对血清白蛋白具有结合特异性的设计的锚蛋白重复结构域，以及编码这样的核酸 设计的锚蛋白重复结构域和重组结合蛋白，包含这种设计的锚蛋白重复结构域的药物组合物，重组结合蛋白或核酸，以及这些设计的锚蛋白重复结构域，重组结合蛋白，核酸或药物组合物在治疗疾病中的用途。

公开(公告)号：WO2016116948A1

公开(公告)日：2016-07-28

申请号：PCT/IN2016/000025

申请日：2016-01-21

Applicant: RAM, Isanaka

Inventor： RAM, Isanaka

IPC: A61K38/20 ,  C07K14/54

CPC classification number: C07K14/4703 ,  A61K38/00 ,  A61K38/20 ,  C07K14/54

Abstract: The present invention provides a peptide having anti-inflammatory activity. The present invention also provides the method of preparation of the peptide and compositions, and kits comprising the peptide. The invention further provides the method of treating inflammatory diseases employing the peptide of the present invention.

Abstract translation: 本发明提供具有抗炎活性的肽。 本发明还提供了肽和组合物的制备方法以及包含该肽的试剂盒。 本发明还提供了使用本发明的肽治疗炎性疾病的方法。

公开(公告)号：WO2016112292A1

公开(公告)日：2016-07-14

申请号：PCT/US2016/012650

申请日：2016-01-08

Applicant: MOERAE MATRIX, INC.

Inventor： LANDER, Cynthia ,  BROPHY, Colleen ,  PETERSON, Caryn

IPC: C07K14/47

CPC classification number: C07K14/4703 ,  A61K9/0019 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/145 ,  A61K38/00 ,  A61K38/1709 ,  A61K47/02 ,  A61K47/26 ,  A61K47/32

Abstract: The described invention provides pharmaceutical formulations comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1 ) or a functional equivalent thereof with improved stability and bioavailability. According to one embodiment, the pharmaceutical formulation is a particulate pharmaceutical formulation. According to another aspect, the described invention provides a method for treating a vascular graft-induced intimal hyperplasia in a subject in need of such treatment.

Abstract translation: 所述发明提供包含具有改善的稳定性和生物利用度的氨基酸序列YARAAARQARAKALARQLGVAA（SEQ ID NO：1）或其功能等同物的多肽的药物制剂。 根据一个实施方案，药物制剂是颗粒药物制剂。 根据另一方面，本发明提供了治疗需要这种治疗的受试者的血管移植物诱导的内膜增生的方法。

公开(公告)号：WO2016075309A1

公开(公告)日：2016-05-19

申请号：PCT/EP2015/076603

申请日：2015-11-13

Applicant: BERGENBIO AS

Inventor： MICKLEM, David Robert ,  HELLESOY, Monica ,  NILSSON, Linn Hodneland

IPC: G01N33/574

CPC classification number: C12Q1/6886 ,  A61K31/502 ,  C07K14/4703 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N33/5088 ,  G01N33/574 ,  G01N33/57426 ,  G01N33/57484 ,  G01N33/57496 ,  G01N2333/4704 ,  G01N2500/10 ,  G01N2800/52 ,  G01N2800/56

Abstract: The use of Slfn11 as a biomarker for detecting the occurrence of epithlial-to-mesenchymal transition (EMT) in a subject, and the use of Slfn11 modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Slfn11 expression and/or activity.

Abstract translation: 本文公开了使用Slfn11作为检测受试者中上皮细胞间质转化（EMT）的发生的生物标志物，以及使用Slfn11调节剂治疗癌症。 还公开了通过测量Slfn11表达和/或活性来检测受试者中上皮 - 间质转换（EMT）的发生的各种方法。

公开(公告)号：WO2016063264A1

公开(公告)日：2016-04-28

申请号：PCT/IB2015/058202

申请日：2015-10-23

Applicant: OSPEDALE SAN RAFFAELE S.R.L. ,  FONDAZIONE TELETHON

Inventor： NALDINI, Luigi ,  LOMBARDO, Angelo Leone ,  AMABILE, Angelo ,  MIGLIARA, Alessandro

IPC: C12N15/85 ,  A61K48/00 ,  A61K38/45 ,  C12N9/10

CPC classification number: C12N9/1007 ,  A61K35/12 ,  A61K38/1709 ,  A61K38/45 ,  A61K48/005 ,  C07K14/4703 ,  C07K2319/80 ,  C12N2740/16043 ,  C12Y201/01037 ,  C12Y201/01043

Abstract: A product comprising two or more artificial transcription repressors (ATRs), or polynucleotides encoding therefor, selected from groups (a), (b), (c) or (d): (a) an ATR comprising a DNA-binding domain operably linked to a KRAB domain or homologue thereof; (b) an ATR comprising a DNA-binding domain operably linked to a DNMT3A, DNMT3B or DNMT1 domain or homologue thereof; (c) an ATR comprising a DNA-binding domain operably linked to a DNMT3L domain or homologue thereof; and (d) an ATR comprising a DNA-binding domain operably linked to a SETDB1 domain or homologue thereof, wherein at least two of the ATRs are selected from different groups (a), (b), (c) or (d).

Abstract translation: 选自（a），（b），（c）或（d）组的两种或更多种人工转录阻抑物（ATR）或其编码的多核苷酸的产物：（a）包含可操作地连接的DNA结合结构域的ATR 到KRAB结构域或其同源物; （b）ATR，其包含与DNMT3A，DNMT3B或DNMT1结构域或其同源物可操作地连接的DNA结合结构域; （c）包含可操作地连接到DNMT3L结构域或其同源物的DNA结合结构域的ATR; 和（d）ATR，其包含可操作地连接到SETDB1结构域或其同源物的DNA结合结构域，其中至少两个ATR选自不同的组（a），（b），（c）或（d）。

公开(公告)号：WO2016057975A2

公开(公告)日：2016-04-14

申请号：PCT/US2015/055022

申请日：2015-10-09

Applicant: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL

Inventor： MENDELL, Jerry, R. ,  KASPAR, Brian, K. ,  AL-ZAIDY, Samiah

IPC: A61K38/18

CPC classification number: A61K48/0075 ,  A61K38/1709 ,  A61K48/00 ,  C07K14/4703 ,  C12N7/00 ,  C12N15/86 ,  C12N2750/14142 ,  C12N2750/14143 ,  C12N2750/14171 ,  C12N2799/025

Abstract: The disclosure relates to methods for treating subjects with musculoskeletal diseases or with muscle wasting not associated with a musculoskeletal disease by gene transfer with recombinant adeno-associated viruses (rAAV) encoding myostatin inhibitors such as follistatin-344. The rAAV are administered prior to development of diffuse muscle fibrosis in a subject, or the rAAV administration avoids regions of muscle fibrosis in a subject.

Abstract translation: 本公开涉及通过用编码肌肉生长抑制素（例如卵泡抑素-444）的重组腺相关病毒（rAAV）进行基因转移来治疗具有肌肉骨骼疾病的受试者或与肌肉骨骼疾病无关的肌肉消耗的方法。 在受试者发展弥漫性肌肉纤维化之前施用rAAV，或者rAAV给药避免受试者的肌肉纤维化区域。